Thales Laser on Mars 2020 Mission: Three Days to Touchdown
16.2.2021 01:40:00 EET | Business Wire | Press release
On 18 February, the Perseverance rover — a key component of the Mars 2020 mission — will touch down on the Red Planet after a long seven-month voyage. SuperCam, one of seven strategic onboard instruments, is a powerful combination of technologies designed to analyse, characterise and select Martian rock samples. SuperCam is the result of close collaboration between Los Alamos National Laboratory (LANL) in the United States and the astrophysics and planetology research institute in France (IRAP, CNRS / CNES / Université Toulouse III - Paul Sabatier), with contributions from the University of Hawaii and the University of Valladolid in Spain. The Mast Unit, the French part of SuperCam located at the top of the rover’s mast, was designed and built by a consortium of French laboratories1 from CNRS, universities and entities under the scientific lead of the IRAP team and under the responsibility of CNES, the French space agency. The laser supplied by Thales is a key part of the Mast Unit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210215005423/en/
Credits: NASA
In 2012, Curiosity landed on Mars equipped with the first high-power laser to operate on the surface of another planet, a laser designed and developed by Thales for the ChemCam instrument. The ChemCam laser has been operating faultlessly for over eight years and has fired close to 855,000 shots to date as Curiosity has made its 24-kilometre trek across the surface of the Red Planet. Data from ChemCam has already helped to prove that conditions on Mars were once suitable for microbial life.
The SuperCam instrument, a new and more powerful version of ChemCam, is designed to take Mars exploration to a new level. Like ChemCam, the SuperCam laser will use an infrared beam to heat material to a temperature of around 10,000°C and vaporise it — a method called laser induced breakdown spectroscopy. Coupled with a special camera, this makes it possible to determine the chemical composition of Martian rock samples by measuring the colours of light in the plasma created.
Unlike ChemCam, however, the SuperCam laser can also emit a green laser beam, which will help determine the molecular composition of surface materials. This green beam excites the chemical bonds in samples and produces a different signal according to their various linked components. This analysis technique, known as Raman spectroscopy, will be tested for the first time on Mars and will enable scientists to detect any markers of life. The green laser will also be used to induce fluorescence in mineral and organic compounds, allowing scientists to determine their constituent components with greater accuracy.
“We’re proud to have provided NASA with the first two lasers to operate on Mars. The Mars 2020 mission is a decisive step forward in the study of the Red Planet and preparations for future expeditions. SuperCam, the ‘eyes’ of Perseverance, is the result of close collaboration between partners across the international scientific community. Thales's SuperCam laser delivers unrivalled performance and will enable Perseverance to perform its exploration mission throughout its time on the surface of Mars.” Christophe Salomon, Executive Vice President, Land and Air Systems
About Mars 2020
The goal of the Mars 2020 mission is to study the Red Planet’s surface, search for signs of past life, take rock and dust samples at selected sites and store them for retrieval by the future Mars Sample Return (MSR) mission, which will be conducted jointly with the European Space Agency. Thales Alenia Space is closely involved in the MSR mission.
The Mars 2020 mission is designed to gather the necessary knowledge and test the technologies that will be vital for future human expeditions to the Red Planet.
How to produce oxygen from the Martian atmosphere? What resources are available? Is there water beneath the surface, for example? How to improve landing techniques and characterise weather conditions, dust levels and other environmental conditions that could affect the life and work of future astronauts on Mars? These are just some of the questions the Perseverance mission will seek to answer.
About Thales lasers
For more than 35 years, Thales has been a world leader in design, development and manufacturing of high energy nanosecond lasers for industrial applications and the most powerful ultra-short Ti:Sa femtosecond laser systems for leading scientific applications with peak power up to 10 petawatts.
Thales provides the most reliable and easy-to-use products, a unique combination of technological expertise and robustness for implementation into industrial applications that require highest availability such as laser annealing, laser lift-off, laser shock peening and cutting of composites for various industries such as aerospace, microelectronics, flat panel displays and many others. Thales provides also a full range of services, which are optimized to support each customer.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
[1] The Irap ; the Laboratoire d’études spatiales et d’instrumentation en astrophysique (LESIA, Observatoire de Paris-PSL/CNRS/SU/Université de Paris) ; the Laboratoire d’astrophysique de Bordeaux (LAB, CNRS/Université de Bordeaux) ; the Laboratoire « atmosphères et observations spatiales » (LATMOS, CNRS/SU/UVSQ) ; l’Observatoire Midi-Pyrénées (OMP, CNRS/IRD/Météo-France/Université de Toulouse III – Paul Sabatier) ; the Institut d’astrophysique spatiale (IAS, CNRS/Université Paris-Saclay).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005423/en/
Contact information
PRESS
Thales, Media Relations
Group and Innovation
Alice Pruvot
+33 (0)7 70 27 11 37
alice.pruvot@thalesgroup.com
Thales Alenia Space, Media Relations
Sandrine Bielecki
+33 (0)4 92 92 70 94
sandrine.bielecki@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
